Maintaining a Hold: AlloVir's Strategic Uncertainty and Financial Outlook

TipRanksMar 19 01:35 ET

ALLOVIR SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options

If you suffered losses exceeding $25,000 investing in AlloVir stock or options between March 22, 2022 and December 21, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson

GlobeNewswireFeb 23 10:30 ET

AlloVir Faces Delisting Risk, Considers Reverse Split to Comply

TipRanksFeb 12 16:43 ET

AlloVir(ALVR.US) Officer Sells US$7,493.92 in Common Stocks

$AlloVir(ALVR.US)$ Officer Hagen Brett R sold 11,150 shares of Common Stocks on Feb 8, 2024 at an average price of $0.6721 for a total value of $7,493.92.Source: Announcement What is statement of chan

moomoo NewsFeb 9 20:43 ET

Top 4 Health Care Stocks That May Rocket Higher In Q1

The most oversold stocks in the health care presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to i

BenzingaJan 16 06:50 ET

AlloVir To Cut 95% of Workforce After Discontinuing Trials

By Ben Glickman AlloVir will cut about 95% of its current employee base after scrapping three late-stage clinical trials. The cell-therapy developer said in a regulatory filing Thursday that the lay

WSJJan 4 18:00 ET